Ucb Pharma, S.a.

Ucbbiopharma Srl

Ucb Biopharma Sprl

Stevan Graham Shaw

Alastair David Griffiths Lawson

Kerry Louise Tyson

Andrew George Popplewell

Helene Margaret Finney

Yi Lin Zhang

Bryan John Smith

Lara Kevorkian

Paul Alan Atherfold

Kaushik Sarkar

Andrew Malcolm Nesbitt

Diana Shpektor

Christoph Meier

Alastair David Lawson

Diane Marshall

Ruth Oliver

Foteini Strimenopoulou

Venkata Pavan Kumar Vajjah

Sophie Glatt

Lucian Ionescu

Margaret Jones

Yi Zhang

The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.

Anti-FcRn antibodies

The invention relates to therapeutic uses of antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F in the treatment of dermatological and rheumatological diseases, such as psoriasis, psoriatic arthritis and axial spondyloarthritis.

Methods of treatment using anti-IL-17A/F antibodies

The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.

Antibody molecules having specificity for human OX40

The present invention provides a method for the treatment and/or prophylaxis of glomerulonephritis associated with one or more disorders selected from the group consisting of Goodpasture's syndrome, a vasculitic disorder, Wegener's disease, IgA nephropathy and an inflammatory disease with basement membrane involvement comprising administering a therapeutically effective amount of agent which interacts with or modulates the expression or activity of a mammalian IL-6 polypeptide.

Method for the treatment of glomerulonephritis by administering an IL-6 antibody

Growing community of inventors

Slough, United Kingdom

Stevan Graham Shaw